Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline Review, H2 2016, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape.
Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 1, 2, 9, 1 and 1 respectively.Polyarticular Juvenile Idiopathic Arthritis (PJIA).
Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Biocon Ltd
Coherus BioSciences Inc
Livzon Pharmaceutical Group Inc
Marathon Pharmaceuticals LLC
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
NeuClone Pty Ltd
Oncobiologics Inc
Oncodesign SA
Panacea Biotec Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview 7
Therapeutics Development 8
Pipeline Products for Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview 8
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics under Development by Companies 9
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Products under Development by Companies 14
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development 15
Biocon Ltd 15
Coherus BioSciences Inc 16
Livzon Pharmaceutical Group Inc 17
Marathon Pharmaceuticals LLC 18
Momenta Pharmaceuticals Inc 19
Mycenax Biotech Inc 20
NeuClone Pty Ltd 21
Oncobiologics Inc 22
Oncodesign SA 23
Panacea Biotec Ltd 24
Regeneron Pharmaceuticals Inc 25
Sandoz International GmbH 26
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
abatacept biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
adalimumab biosimilar - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
adalimumab biosimilar - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
adalimumab biosimilar - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
adalimumab biosimilar - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
adalimumab biosimilar - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
adalimumab biosimilar - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
deflazacort - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
etanercept biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
etanercept biosimilar - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
etanercept biosimilar - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
etanercept biosimilar - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
etanercept biosimilar - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
methotrexate - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
sarilumab - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
tocilizumab biosimilar - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
tocilizumab biosimilar - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
tocilizumab biosimilar - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects 65
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones 66
Featured News & Press Releases 66
Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) 66
Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel 66
Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H2 2016 15
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H2 2016 16
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2016 17
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Marathon Pharmaceuticals LLC, H2 2016 18
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H2 2016 19
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H2 2016 20
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by NeuClone Pty Ltd, H2 2016 21
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H2 2016 22
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H2 2016 23
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Ltd, H2 2016 24
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H2 2016 65
List of Figures
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Targets, H2 2016 28
Number of Products by Stage and Targets, H2 2016 28
Number of Products by Mechanism of Actions, H2 2016 30
Number of Products by Stage and Mechanism of Actions, H2 2016 30
Number of Products by Routes of Administration, H2 2016 32
Number of Products by Stage and Routes of Administration, H2 2016 32
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34
